AU2023265422A1 - Multiplexed t cell receptor compositions, combination therapies, and uses thereof - Google Patents

Multiplexed t cell receptor compositions, combination therapies, and uses thereof Download PDF

Info

Publication number
AU2023265422A1
AU2023265422A1 AU2023265422A AU2023265422A AU2023265422A1 AU 2023265422 A1 AU2023265422 A1 AU 2023265422A1 AU 2023265422 A AU2023265422 A AU 2023265422A AU 2023265422 A AU2023265422 A AU 2023265422A AU 2023265422 A1 AU2023265422 A1 AU 2023265422A1
Authority
AU
Australia
Prior art keywords
hla
cell
tcr
cells
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023265422A
Other languages
English (en)
Inventor
Cagan Gurer
Gavin Macbeath
Yifan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tscan Therapeutics Inc
Original Assignee
Tscan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tscan Therapeutics Inc filed Critical Tscan Therapeutics Inc
Publication of AU2023265422A1 publication Critical patent/AU2023265422A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/427—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Data Exchanges In Wide-Area Networks (AREA)
AU2023265422A 2022-05-02 2023-04-28 Multiplexed t cell receptor compositions, combination therapies, and uses thereof Pending AU2023265422A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263337522P 2022-05-02 2022-05-02
US63/337,522 2022-05-02
US202263342451P 2022-05-16 2022-05-16
US63/342,451 2022-05-16
US202263413553P 2022-10-05 2022-10-05
US63/413,553 2022-10-05
US202263423269P 2022-11-07 2022-11-07
US63/423,269 2022-11-07
PCT/US2023/020338 WO2023215183A1 (en) 2022-05-02 2023-04-28 Multiplexed t cell receptor compositions, combination therapies, and uses thereof

Publications (1)

Publication Number Publication Date
AU2023265422A1 true AU2023265422A1 (en) 2024-10-24

Family

ID=88646870

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023265422A Pending AU2023265422A1 (en) 2022-05-02 2023-04-28 Multiplexed t cell receptor compositions, combination therapies, and uses thereof

Country Status (12)

Country Link
US (1) US20250288675A1 (cg-RX-API-DMAC7.html)
EP (1) EP4519305A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025516264A (cg-RX-API-DMAC7.html)
KR (1) KR20250006149A (cg-RX-API-DMAC7.html)
CN (1) CN119487060A (cg-RX-API-DMAC7.html)
AU (1) AU2023265422A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248253A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024016274A2 (cg-RX-API-DMAC7.html)
IL (1) IL316250A (cg-RX-API-DMAC7.html)
MX (1) MX2024013482A (cg-RX-API-DMAC7.html)
TW (1) TW202406569A (cg-RX-API-DMAC7.html)
WO (1) WO2023215183A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024005746A (es) * 2021-11-10 2024-07-19 Tscan Therapeutics Inc Peptidos inmunogenicos magea1, proteinas de union que reconocen peptidos inmunogenicos magea1, y usos de estos.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113595A2 (en) * 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
NZ741124A (en) * 2012-07-27 2019-11-29 Univ Illinois Engineering t-cell receptors
JP6895975B2 (ja) * 2016-01-06 2021-06-30 ヘルス リサーチ インコーポレイテッドHealth Research, Inc. 組換えt細胞受容体を含む組成物及びライブラリー並びに組換えt細胞受容体を使用する方法
KR20190062505A (ko) * 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
JP7289028B2 (ja) * 2018-09-05 2023-06-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 複数の主要組織適合遺伝子複合体分子に制限したny-eso-1-特異的t細胞受容体の組成物
WO2020167957A1 (en) * 2019-02-12 2020-08-20 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
DE102019121007A1 (de) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
EP4010377A4 (en) * 2019-08-09 2023-09-06 A2 Biotherapeutics, Inc. CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS

Also Published As

Publication number Publication date
EP4519305A1 (en) 2025-03-12
KR20250006149A (ko) 2025-01-10
IL316250A (en) 2024-12-01
CN119487060A (zh) 2025-02-18
EP4519305A4 (en) 2026-05-06
TW202406569A (zh) 2024-02-16
JP2025516264A (ja) 2025-05-27
WO2023215183A1 (en) 2023-11-09
CA3248253A1 (en) 2023-11-09
US20250288675A1 (en) 2025-09-18
CO2024016274A2 (es) 2024-12-09
MX2024013482A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
US20230203124A1 (en) Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
AU2021202223B2 (en) Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
US12570718B2 (en) PD-1-CD28 fusion proteins and their use in medicine
US12589151B2 (en) T cell modification
US20190119350A1 (en) Ny-eso-1 specific tcrs and methods of use thereof
KR20220002336A (ko) T 세포 치료제를 제조하기 위한 생체외 방법 및 관련 조성물 및 방법
US20240270813A1 (en) T CELL RECEPTORS (TCRs) TARGETING MINOR HISTOCOMPATIBILITY ANTIGEN HA-1
US20250288675A1 (en) Multiplexed t cell receptor compositions, combination therapies, and uses thereof
EP4253410A1 (en) Ras mutant epitope peptide and t cell receptor recognizing ras mutant
HK40064520A (en) Pd1-cd28 fusion proteins and their use in medicine
HK40109405A (en) Pd1-cd28 fusion proteins and their use in medicine
WO2025217035A2 (en) Use of anti-ha-1 and anti-ha-2 binding proteins for treatment of aml, all, and mds
HK40064520B (en) Pd1-cd28 fusion proteins and their use in medicine
HK40117446A (en) T cell modification
WO2025217037A2 (en) Use of binding proteins for treatment of solid tumors
WO2026007901A1 (zh) 共表达细胞因子的FLT3-CAR-γδT细胞及其应用